CVM News & Events

CEL-SCI highlighted its dual-track strategy to bring Multikine to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia. The Company plans to commence its Confirmatory Registration Study of Multikine this summer while simultaneously advancing regulatory and commercialization activities in Saudi Arabia through its strategic partnership with Saudi Amarox. "Following extensive clinical development and close engagement with regulators, we are excited to begin our final Confirmatory Registration Study, aiming to extend lives and improve the quality of life for head and neck cancer patients," said Geert Kersten, Chief Executive Officer of CEL-SCI. "We are also looking forward to participating in next week's signing ceremony at BIO with Amarox, our Saudi partner, as we advance a second pathway to bring Multikine to patients."

CEL-SCI Corporation announced it will participate in a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego, California. The ceremony will mark a milestone in advancing the previously announced strategic agreement between the companies focused on the commercialization and distribution of Multikine in the Kingdom of Saudi Arabia. The official signing ceremony will take place during the opening ceremony of the Saudi Amarox booth on Monday, June 22, 2026.

"During the fiscal second quarter, we made significant progress advancing Multikine toward potential commercialization and regulatory approval in multiple markets," stated CEL-SCI CEO Geert Kersten. "Our strategic partnership with Amarox represents an important milestone for CEL-SCI, providing a pathway to potential early commercialization and revenue generation for Multikine in Saudi Arabia through the SFDA's Breakthrough Medicine Designation process as well as potential market access in the GCC countries. At the same time, we are starting efforts to initiate patient enrollment in our pivotal U.S. FDA Confirmatory Registration Study later this summer/fall. We believe the study's design, which allows for rapid assessment of pre-surgical tumor response following a short course of Multikine treatment, may provide an opportunity to pursue accelerated approval in the U.S. With strengthening financial support, continued management investment in the Company, and increasing international interest in Multikine, we believe CEL-SCI is entering an inflection point."